Controlling postprandial hyperglycemia

  • Robert E Ratner
    Address for reprints: Robert E. Ratner, MD, Medstar Research Institute, 650 Pennsylvania Avenue SE, Suite 50, Washington, DC 20003-4393
    Medstar Research Institute, Washington, DC, USA
    Search for articles by this author


      A growing body of evidence indicates that measurements of postprandial glucose levels, in combination with glycosylated hemoglobin, are a more accurate predictor of metabolic abnormality than fasting or preprandial glucose levels for individuals with type 2 diabetes. Early identification of elevated postprandial blood glucose levels is an important step in predicting the onset of microvascular and macrovascular complications that can progress to full symptomatic diabetes. This article summarizes the research conducted to date on the diagnostic import of postprandial glucose and the parameters established for judging the need for treatment. When individuals cannot reach target glucose levels through diet and exercise, medical treatment is necessary. The article reviews a range of treatment options, including insulin secretagogues, insulin sensitizers, antiabsorptive agents, weight reduction agents, and insulin and combination medical therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lebovitz H.E
        Postprandial hyperglycaemic state.
        Diabetes Res Clin Pract. 1998; 40: S27-S28
        • Baron A.D
        Postprandial hyperglycaemia and α-glucosidase inhibitors.
        Diabetes Res Clin Pract. 1998; 40: S51-S55
        • American Diabetes Association
        Standards of care for patients with diabetes mellitus.
        Diabetes Care. 2000; 23: S32-S42
        • Avignon A
        • Radauceanu A
        • Monnier L
        Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.
        Diabetes Care. 1997; 20: 1822-1826
        • Baron A.D
        Impaired glucose tolerance as a disease.
        Am J Cardiol. 2001; 88: 16F-19F
      1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23(suppl 1):S4–S19.

        • The Diabetes Control and Complications Trial Research Group
        The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
        N Engl J Med. 1993; 329: 977-986
        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • King P
        • Peacock I
        • Donnelly R
        The UK Prospective Diabetes Study (UKPDS).
        Br J Pharmacol. 1999; 48: 643-648
        • Turner R.C
        • Cull C.A
        • Frighi V
        • Holman R.R
        • UK Prospective Diabetes Study (UKPDS) Group
        Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes.
        JAMA. 1999; 281: 2005-2012
        • Abraira C
        • McGuire D.K
        Intensive insulin therapy in patients with type 2 diabetes.
        Am Heart J. 1999; 138: 360-365
        • Abraira C
        • Colwell J
        • Nuttall F
        • Sawin C.T
        • Henderson W
        • Comstock J.P
        • Emanuele N.V
        • Levin S.R
        • Pacold I
        • Lee H.S
        Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial.
        Arch Intern Med. 1997; 157: 181-188
        • de Veciana M
        • Major C.A
        • Morgan M.A
        • Asrat T
        • Toohey J.S
        • Lien J.M
        • Evans A.T
        Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes requiring insulin therapy.
        N Engl J Med. 1995; 333: 1237-1241
        • Jovanovic-Peterson L
        • Petersen C.M
        • Reed G.F
        • Metzger B.E
        • Mills J.L
        • Knopp R.H
        • Aarons J.H
        Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development.
        Am J Obstet Gynecol. 1991; 164: 103-111
      2. Ilic S, Jovanovic L, Jeng L. What is the optimal postprandial glucose monitoring system in gestational diabetes? Presented at the 36th Annual Meeting of the European Association for the Study of Diabetes. Jerusalem, Israel, September 17–21, 2000.

        • American Diabetes Association
        The pharmacological treatment of hyperglycemia in NIDDM.
        Diabetes Care. 1995; 18: 1510-1518
        • Buse J.B
        Overview of current therapeutic options in type 2 diabetes.
        Diabetes Care. 1999; 22: C65-C70
        • Ashcroft F.M
        Mechanisms of the glycaemic effects of sulfonylureas.
        Horm Metab Res. 1996; 28: 456-463
        • Simonson D.C
        • Kourides I.A
        • Feinglos M
        • Shamoon H
        • Fischette C.T
        Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM.
        Diabetes Care. 1997; 20: 597-606
        • Kilo C
        Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus.
        Clin Ther. 1988; 10: 294-302
        • Langtry H.D
        • Balfour J.A
        Drugs. 1998; 55: 563-584
        • Schade D.S
        • Jovanovic L
        • Schneider J
        A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.
        J Clin Pharmacol. 1998; 38: 636-641
        • Ratner R.E
        Repaglinide therapy in the treatment of type 2 diabetes.
        Today’s Ther Trends. 1999; 7: 57-66
        • Fuhlendorff J
        • Rorsman P
        • Kofod H
        • Brand C.L
        • Rolin B
        • MacKay P
        • Shymko R
        • Carr R.D
        Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
        Diabetes. 1998; 47: 345-351
        • Marbury T
        • Huang W.C
        • Strange P
        • Lebovitz H
        Repaglinide versus glyburide.
        Diabetes Res Clin Pract. 1999; 43: 155-166
        • Keilson L
        • Mather S
        • Walter Y.H
        • Subramanian S
        • McLeod J.F
        Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2000; 85: 1081-1086
        • DeFronzo R.A
        • Goodman A.M
        • Multicenter Metformin Study Group
        Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus.
        N Engl J Med. 1995; 333: 541-549
        • Garber A.J
        • Duncan T.G
        • Goodman A.M
        • Mills D.J
        • Rohlf J.L
        Efficacy of metformin in type II diabetes.
        Am J Med. 1997; 103: 491-497
        • Inzucchi S.E
        • Maggs D.G
        • Spollett G.R
        • Page S.L
        • Rife F.S
        • Walton V
        • Shulman G.I
        Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
        N Engl J Med. 1998; 338: 867-872
        • Saltiel A.R
        • Olefsky J.M
        Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
        Diabetes. 1996; 45: 1661-1669
        • Grunberger G
        • Weston W.M
        • Patwardhan R
        • Rappaport E.B
        Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes.
        Diabetes. 1999; 48 ([abstract]): A102
        • Raskin P
        • Rappaport E.B
        • Cole S.T
        • Yan Y
        • Patwardan R
        • Freed M.I
        Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
        Diabetologia. 2000; 43: 278-284
        • Henney J.A
        New type 2 diabetes drugs.
        JAMA. 1999; 282: 932
        • Lebovitz H.E
        Alpha-glucosidase inhibitors.
        Endocrinol Metab Clin North Am. 1997; 26: 539-551
        • Chiasson J.L
        • Josse R.G
        • Hunt J.A
        • Palmason C
        • Rodger N.W
        • Ross S.A
        • Ryan E.A
        • Tan M.H
        • Wolever T.M
        The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus after oral agent failure.
        Clin Ther. 1994; 121: 928-935
        • Holman R.R
        • Cull C.A
        • Turner R.C
        A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years.
        Diabetes Care. 1999; 22: 960-964
        • Hauner H
        The impact of pharmacotherapy on weight management in type 2 diabetes.
        Int J Obes Relat Metab Disord. 1999; 23: S12-S17
        • Hollander P.A
        • Elbein S.C
        • Hirsch I.B
        • Kelley D
        • McGill J
        • Taylor T
        • Weiss S.R
        • Crockett S.E
        • Kaplan R.A
        • Comstock J
        • et al.
        Role of orlistat in the treatment of obese patients with type 2 diabetes.
        Diabetes Care. 1998; 21: 1288-1294
        • Ratner R.E
        Type 2 diabetes mellitus: the grand overview.
        Diabet Med. 1998; 15: S4-S7
        • Ovalle F
        • Belle D.S.H
        Triple oral antidiabetic therapy in type 2 diabetes mellitus.
        Endocr Pract. 1998; 4: 146-147
        • Mooradian A.D
        • Thurman J.E
        Drug therapy of postprandial hyperglycemia.
        Drugs. 1999; 57: 19-29
        • Raskin P
        • Riis A
        • Guthrie R.A
        • Jovanovic L
        • Leiter L
        Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
        Diabetes Care. 2000; 23: 583-588